Literature DB >> 31445721

Bioprosthetic Valve Fracture for Valve-in-Valve Transcatheter Aortic Valve Replacement: Rationale, Patient Selection, Technique, and Outcomes.

Mary Rodriguez Ziccardi1, Elliott M Groves2.   

Abstract

Patient-prosthesis mismatch (PPM) is common after surgical valve aortic replacement. A significant percentage of patients with a small annulus have moderate to severe PPM. The outcomes for patients with larger effective orifice areas and lower gradients are better than for patients with PPM. With the advent of valve-in-valve TAVR, a degenerated surgical bioprosthesis can be treated with a percutaneous approach. However, the issue of PPM cannot be overcome by simply implanting a new valve. The technique of bioprosthetic valve fracture was therefore developed. This allows for implantation of a fully expanded transcatheter valve and results in a large effective orifice. Published by Elsevier Inc.

Entities:  

Keywords:  Bioprosthetic valve; Fracture; Patient prosthesis mismatch; TAVR; Valve in valve

Mesh:

Year:  2019        PMID: 31445721     DOI: 10.1016/j.iccl.2019.05.004

Source DB:  PubMed          Journal:  Interv Cardiol Clin        ISSN: 2211-7458


  3 in total

1.  Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes.

Authors:  Sameer A Hirji; Edward D Percy; Cheryl K Zogg; Alexandra Malarczyk; Morgan T Harloff; Farhang Yazdchi; Tsuyoshi Kaneko
Journal:  Eur Heart J       Date:  2020-08-01       Impact factor: 29.983

2.  Ring Fracture of Brazilian Aortic Valve Bioprostheses Using Non-Compliant High-Pressure Transcatheter Balloon, an Ex Vivo Test.

Authors:  Andre Lupp Mota; Diego Felipe Gaia; José Honório Palma da Fonseca
Journal:  Braz J Cardiovasc Surg       Date:  2022-05-23

Review 3.  Management of Failed Bioprosthetic Aortic Valves: Mitigating Complications and Optimizing Outcomes.

Authors:  Elizabeth L Norton; Alison F Ward; Adam Greenbaum; Kendra J Grubb
Journal:  J Interv Cardiol       Date:  2022-09-02       Impact factor: 1.776

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.